Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Current Clinical Pharmacology

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/157488406776872532PMID 18666366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

  2005cited by this paper
• Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan

  2005cited by this paper
• Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES)

  2005cited by this paper
• Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.

  2005cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide

  2004cited by this paper
• Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity

  2004cited by this paper
• Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.

  2004cited by this paper
• Stroke prevention with losartan in the context of other antihypertensive drugs.

  2004cited by this paper
• Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity

  2004cited by this paper
• Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation

  2004cited by this paper
• Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Int

  2004cited by this paper
• Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).

  2004cited by this paper
• Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

  2004cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003cited by this paper
• Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

  2003cited by this paper
• Long-Term Effects of Irbesartan and Atenolol on the Renin-Angiotensin-Aldosterone System in Human Primary Hypertension: The Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)

  2003cited by this paper
• The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

  2003cited by this paper
• Blood pressure lowering and renin-angiotensin system blockade

  2003cited by this paper
• Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.

  2003cited by this paper
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

  2003cited by this paper
• Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect

  2002cited by this paper
• Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study

  2002cited by this paper
• Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.

  2002cited by this paper
• Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study

  2002cited by this paper
• Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

  2002cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Non-AT1-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil

  2001cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

  2000cited by this paper
• The renin-angiotensin system and experimental heart failure.

  1999cited by this paper
• Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells.

  1999cited by this paper
• Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats.

  1999cited by this paper
• Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.

  1998cited by this paper
• Vascular remodeling: the role of angiotensin-converting enzyme inhibitors.

  1998cited by this paper
• Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation.

  1994cited by this paper
• Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.

  1992cited by this paper
• Does angiotensin-II protect against strokes?

  1986cited by this paper
• Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation.

  1986cited by this paper
• Effects of Diuretics On Lipid Metabolism in Patients With Essential Hypertension

  1976cited by this paper

• Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore.

  2021cites this paper
• COVID-19, Angiotensin Receptor Blockers, and the Brain

  2020cites this paper
• Trends in Angiotensin Receptor Blocker Use Among those at Risk for COVID-19 Morbidity and Mortality in the United States

  2020cites this paper
• Candesartan could ameliorate the COVID-19 cytokine storm

  2020cites this paper
• Angiotensin II AT1 Receptor Blockers Ameliorate Inflammatory Stress: A Beneficial Effect for the Treatment of Brain Disorders

  2012cites this paper
• Stim1- and Orai1-mediated store-operated calcium entry is critical for angiotensin II-induced vascular smooth muscle cell proliferation.

  2012cites this paper
• Stim 1-and Orai 1-mediated store-operated calcium entry is critical for angiotensin II-induced vascular smooth muscle cell proliferation

  2012cites this paper
• Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.

  2011cites this paper